<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>SEROPREVALENCE OF TOXOCARA SPP AMONG EPILEPTIC PATIENTS IN IRAQ/BASRA</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Ban Anas</mods:namePart><mods:namePart type="family">Sabbar</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Assim Khalid</mods:namePart><mods:namePart type="family">Assim</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Nadham Kadham</mods:namePart><mods:namePart type="family">Mahdi</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>To study&amp;nbsp; seroprevalence of Toxocara&amp;nbsp; antibody Immunoglobulin G (IgG) and epidemiological risk factors as well as assessment&amp;nbsp; the immunological pattern including cytokines, interleukin-6&amp;nbsp; (IL6) and&amp;nbsp; interleukin-10 (IL-10) and immunoglobulin E (IgE) among epileptic patients in Basra province . Subjects and Methods: Forty seven epileptic patients, their ages range from 2.5 - 45 years (22 females and 25 males)&amp;nbsp; and 109 apparently healthy volunteers&amp;nbsp; as&amp;nbsp; a control group with ages range between 2 - 80 years (59 females and 50 males ) were enrolled in this study. The study was done during the period from&amp;nbsp; December 2017 to November 2018 at&amp;nbsp;&amp;nbsp;&amp;nbsp; The Pediatric and Neurology Consulting Clinic&amp;nbsp;&amp;nbsp; of Basra Teaching Hospital. The risk and epidemiologic factors&amp;nbsp; were&amp;nbsp; assessed&amp;nbsp;&amp;nbsp; by&amp;nbsp; a special questionnaire&amp;nbsp; which&amp;nbsp;&amp;nbsp;&amp;nbsp; was&amp;nbsp; completed&amp;nbsp;&amp;nbsp; by&amp;nbsp; the patients&amp;nbsp; themselves&amp;nbsp;&amp;nbsp;&amp;nbsp; or&amp;nbsp;&amp;nbsp; their&amp;nbsp;&amp;nbsp; relative. Immunoglobulin G (IgG) and cytokines were assessed by using ELISA while IgE by immunoturbidimetric&amp;nbsp;&amp;nbsp;&amp;nbsp; assay by&amp;nbsp; using the Abbott ARCHITECT c System for every epileptic patient as well as control group. Results: Sixteen (34.04%)&amp;nbsp; of epileptic patients were seropositive for Toxocara antibody (IgG ) in comparison with 2 (1.83%) of control group with significant difference between them (p=0.0001). There was no significant association between seropositive&amp;nbsp;&amp;nbsp; and seronegative epileptic patients in regard to characteristic features of the studied population (sex and age) and risk factors (residence, exposure to soil,&amp;nbsp; animal ownership, presence of home garden, onychophagia, thumb sucking, medicine intake, family history, duration of epilepsy&amp;nbsp; and occupation) except geophagia . But interestingly, there were&amp;nbsp;&amp;nbsp; elevated in risk ratio&amp;nbsp; for 5 variables&amp;nbsp;&amp;nbsp;&amp;nbsp; including onychophagia (1.7), thumb sucking (2.1), geophagia (3.4), medication intake (1.1) and family history (1.7), when it is evaluated by Chi-squared “Fisher exact test” (risk ratio &amp;gt;1). The immunological assessments&amp;nbsp; reveal an elevation IgE and IL-10 level in seropositive group in comparison seronegative group&amp;nbsp; without a significant difference, while IL-6&amp;nbsp; concentration is elevated in theseronegative group.&amp;nbsp; Conclusion: In epileptic patients in Basra province, infection with Toxocara spp may play role as&amp;nbsp; a risk factor for idiopathic epilepsy. Risk factors such as onychophagia,&amp;nbsp; geophagia, thumb sucking, medication intake and family history may increase risk infection with Toxocara spp in epileptic patients. Also toxocariasis may&amp;nbsp; lead to elevation of&amp;nbsp; IgE and IL-10 levels in these patients but it appears has a weak influence on concentration of IL-6.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2024-04-02</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Research Science and Innovation house</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>